| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| pmx-53 | vasopressin v1a receptor | NA | Successful target | TTD , DGIDB | Dermatitis Atopic[MeSHID:D003876] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Eczema[MeSHID:D004485] |
NA | phase 2 | unknown |
| pmx-53 | c5a anaphylatoxin chemotactic receptor | NA | Clinical trial target | TTD , DGIDB | Dermatitis Atopic[MeSHID:D003876] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Eczema[MeSHID:D004485] |
NA | phase 2 | unknown |
| pmx-53 | albendazole monooxygenase | NA | Clinical trial target | TTD , DGIDB | Dermatitis Atopic[MeSHID:D003876] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Eczema[MeSHID:D004485] |
NA | phase 2 | unknown |
| pmx-53 | melanocortin receptor 4 | NA | Successful target | TTD , DGIDB | Dermatitis Atopic[MeSHID:D003876] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Eczema[MeSHID:D004485] |
NA | phase 2 | unknown |
| pmx-53 | nociceptin receptor | NA | Clinical trial target | TTD , DGIDB | Dermatitis Atopic[MeSHID:D003876] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Eczema[MeSHID:D004485] |
NA | phase 2 | unknown |
| pmx-53 | substance-k receptor | NA | Clinical trial target | TTD , DGIDB | Dermatitis Atopic[MeSHID:D003876] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Eczema[MeSHID:D004485] |
NA | phase 2 | unknown |
| click here to return to the previous page | ||||||||